Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia;Efectividad y seguridad del ácido nicotínico en el tratamiento de la hiperlipidemia asociada a hiperfosfatemia en pacientes con enfermedad renal crónica

Nefrologia

Volumn 28, Issue 1, 2008, Pages 61-66

  Restrepo Valencia, Cesar Augusto ^a,b   Cruz, J ^a  

^a Hospital Santa Sofía Manizales   (Colombia)

^b Hospital Santa Sofía de Caldas   (Colombia)

Author keywords

Chronic renal failure; Hyperlipidaemia; Hyperphosphatemia; Nicotinic acid

Indexed keywords

ANTILIPEMIC AGENT; NICOTINIC ACID;

ARTICLE; CHRONIC DISEASE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERPHOSPHATEMIA; KIDNEY DISEASE; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ANTILIPEMIC AGENTS; CHRONIC DISEASE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; NIACIN; RENAL DIALYSIS;

EID: 47049129447     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Restrepo CA. Desórdenes óseos y minerales en la enfermedad renal crónica en: Nefrología Básica editado por Restrepo C A, 1ra ed, Manizales, editorial la Patria, 2007, capítulo 19, pp. 129-133.
2. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspect of parathyroid hyperplasia in chronic kidney disease. Kidney Int 70: S3-S7, 2006.
3. Dusso AS, Arcidiano MV, Álvarez-Hernández D, Yang J, Gonzáles-Suárez I, Tominaga Y, Slatopolsky E. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int 70: S8-S11, 2006.
4. Bellasi A, Kooienga L, Block GA. Phosphate binders: new products and challenges. Hemodialysis Int 10: 225-234, 2006.
5. Villanueva IB. Hiperlipidemia en la enfermedad renal en: Nefrología Básica editado por Restrepo C A, 1ra ed, Manizales, editorial la Patria, 2007, capítulo 18, pp. 122-127.
6. Foley RN, Murray AM, Li S. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the united states medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495, 2005.
7. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevent the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenina-induced renal failure. Nephrol Dial Transplant 20: 1378-1384, 2005.
8. Debiec H, Lorenc R. Identification of Na, Pi-binding protein in kidney and intestinal brush-border membranes. Biochem J 255: 185-191, 1998.
9. Hilfiker H, Hattenhauer O, Traebert M, Forster I, Murer H, Biber J. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA. 95: 14564-14569, 1998.
10. Field J, Zhang Li, Brun KA, Brooks DP, Edwards RM. Cloning and functional characterization of a sodium dependent phosphate transporter expressed in human lung and small intestine. Bioch Bioph Res Comm 258: 578-582, 1999.
11. K/DOQI Clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41 (Supl. 3): S1-S91, 2003.
12. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca X PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001.
13. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, Phosphate and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770-779, 2004.
14. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004.
15. Young EW, Akiba T, Albert J. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 44 (Supl. 3): S34-S38, 2004.
16. Kestenbaum B, Sampson JN, Rudser KD. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2004.
17. National kidney Foundation. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1-201, 2003.
18. Pohlmeier R, Vienken J. Phosphate removal and hemodialysis conditions. Kidney Int 59 (Supl. 78): S190-S194, 2001.
19. Slatopolsky E, Liapis H, Finch J. progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 68: 2809-2813, 2005.
20. Bover J, Herbener O, Ballarín J, Andrés E, Barceló P. Nuevas estrategias para el hiperparatiroidismo secundario en diálisis (1): nuevos conceptos, nuevos tratamientos. Nefrología 25: 100-108, 2005.
21. Block GA, Spiegel DM, Ehrlich J. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1842, 2005.
22. Asmus HG, Braun J, Krause R. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20: 1653-1661, 2005.
23. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H. Nicotinamide suppresses Hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099. 1 1 0 4 , 2004.
24. Shimoda K, Akiba T, Matsushima T, Rai T, Abe K, Hoshino M. Niceritrol decreases serum phosphate levels in hemodialysis patients. Jpn J Nephrol 40: 1-7, 1998.
25. Shahapuni I, Rahmouni K, Harbouche L, El Esper N, Fournier A. Great cost effectiveness of nicotinamide compared with that sevelamer for controlling hyperphosphatemia in dialysis patients. 2007 World Congress of Nephrology p. 131 (s-po-0311), 2007
26. Sampathkumar K, Sooraj Y, Mahaldar AR, Ramakrishnam M. Comparative efficiency of low dose nicotinic acid and lanthanum in lowering the phosphorus levels in hemodialysis patients. 2007 World Congress of Nephrology p. 136 (s-po-0327), 2007.
27. Krishnaswamy S, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RNP. Extended release nicotinic acid a novel oral agent for phosphate control. Int Urol Nephrol 38: 171-174, 2006.
28. Galeano C, Navarro P, Teruel JL, Ortuño J. Tratamiento de la hiperfosforemia del enfermo dializado con nicotinamida. Nefrología 25: 725-726, 2005.
29. Shimoda K, Akiba T, Matsushima T, Rai T, Hoshino M. Niceritrol decreases serum phosphate levels in hemodialysis patients: a randomized double blind, crossover study. J Am Soc Nephrol 7: S887, 1996.
30. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 14: 610-614, 1999.
31. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, Kuboyama N, Suzuki T, Akiba T, Miyamoto K-I, Takeda E. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14: 1195-1201, 1999.
32. Hattenhauer O, Traebert M, Murer H, Biber J. Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake. Am J Physiol 277: G756-G762, 1999.
33. Huber K, Walter C, Schroder B, Breves G. Phosphate transport in the duodenum and jejunum of goats and its adaptation by dietary phosphate and calcium. Am J Physiol 283: R296-R302, 2002.
34. Xu H, Bai L, Collins JF, Ghishan FK. Age dependent regulation of rat intestine type IIb sodium-phosphate cotransporter by 1,25 (OH)(2) vitamin D (3). Am J Physiol 282: C487-C493, 2002.
35. Berndt TJ, Pfeifer JD, Knox FG, Kempson SA, Dousa TP. Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 242: F447-F452, 1982.
36. Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP. Posible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in rat. J Clin Invest 67: 1347-1360, 1981.
37. Elam MB, Hunninghake DB, Davis KB, Garg R, Jonson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 284: 1263-1270, 2000.
38. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 341: 498-511, 1999.
39. Grundy S, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheean JP. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Inter Med 162: 1568-1576, 2002.
40. Carlson LA. Nicotinic acid and other therapies for raising high-density lipoprotein. Curr Opin Cardiol 21: 336-344, 2006.
41. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, Moers A, Pfeffer K, Offermanns S. GRP109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115: 3634-3640, 2005.
42. Myamoto K, Tatsumi S, Morita K. Takeda E. Does the parathyroid «see» phosphate? Nephrol Dial Transplant 13: 2727-2729, 1998.
43. Delanaye P, Weekers L, Krzesinski J M. diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int 69: 1914, 2006.
44. Rottembourg JB, Launay-Vacher V, Massard J. Trombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68: 2911-2912, 2005.
45. European nicotinamide diabetes intervention trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363: 925-931, 2004.
46. Knip M, Douek IF, Moore WPT, Gillmor HA, McLean AEM, Bingley P J, Gale EAM. Safety of high-dose nocotinamide: a review. Diabetología 43: 1337-1345, 2000.